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INTRODUCTION
Clinicians frequently encounter infiltrative renal masses in their 
practices. These lesions lack a sharp border of demarcation with 
the normal parenchyma, showing ill-defined zones of transition 
between the lesion and normal parenchyma.1 The masses rep-
resent a number of pathologies, such as infiltrative renal cell car-
cinoma (RCC), transitional cell carcinoma (TCC), metastatic 
cancer, medullary carcinoma, renal sarcoma, lymphoma, and 
inflammatory diseases.2 However, due to radiologic similarities 
among these conditions, multi-detector computed tomography 
(MDCT) is not helpful in distinguishing between lesion types. 
Distinguishing infiltrative RCC from TCC is a particularly critical 
process, because of differences in surgical treatment: nephrec-
tomy is carried out in cases of RCC, while nephroureterectomy 
with lymphadenectomy is usually performed in TCC.1,3,4
RCC is the most common type of kidney parenchymal can-
cer, accounting for 85% to 90% of cases.4 About 6% of RCCs 
manifest as infiltrative lesions.1 Meanwhile, TCC of the renal 
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pelvis usually displays an infiltrative growth pattern.2 Both infil-
trative RCC and TCC show up as poorly marginated areas of di-
minished enhancement in MDCT.1 A few studies have tried to 
use CT to differentiate between the two cancers. Raza, et al.2 re-
ported six representative CT findings that could be used to dis-
tinguish centrally located RCC from intrarenal TCC. Bata, et al.3 
reported an additional parameter using attenuation ratios in 
different phases. Nevertheless, Li, et al.5 refuted these two re-
ports, reporting that imaging findings of hypovascular RCC are 
indistinguishable from TCC, and that the clinical application of 
CT in this area is still not acceptable for confirmative diagnoses.
Since RCC is an immunologic cancer,6 our study focused on 
the altered immunology that is characteristic of RCC pathogen-
esis. Several serum biomarkers and hematological indices rep-
resentative of inflammatory response, including C reactive pro-
tein, fibrinogen, absolute monocyte count (AMC), absolute 
neutrophil count (ANC),7 absolute lymphocyte count (ALC),6,8 
lymphocyte-monocyte ratio (LMR),9,10 neutrophil-lymphocyte 
ratio (NLR), and platelet-lymphocyte ratio,11-19 have been inves-
tigated as biomarkers to predict prognosis, oncologic outcomes, 
and treatment responses in RCC patients.20-22 Herein, we hypoth-
esized that systemic inflammatory biomarkers could play a 
major role in distinguishing infiltrative RCC from TCC and at-
tempted to investigate their accuracy in differential diagnosis of 
patients with infiltrative renal masses.
MATERIALS AND METHODS
Good clinical practice protocols
The study was performed in accordance with applicable laws 
and regulations, good clinical practices, and ethical principles 
as described in the Declaration of Helsinki. Severance Hospital 
Institutional Review Board approved this study protocol (Ap-
proval number: 4-2016-0021).
Study design
We retrospectively reviewed a database of RCC and TCC pa-
tients whose diagnoses were not confirmed in preoperative 
MDCT imaging. A total of 117 patients from November 2005 to 
October 2015 with typically infiltrative renal masses were fur-
ther assessed. They were confirmatively diagnosed by either 
surgical resection or percutaneous needle biopsy. From this 
initial cohort, 25 patients were excluded due to inability to un-
dergo pathological diagnosis for personal reason or incomplete 
preoperative blood test or other pathologic findings, such as 1) 
acute pyelonephritis (n=5), 2) spindle cell sarcoma (n=3), 3) 
other primary cancer metastasis (n=3), and 4) oncocytoma 
(n=1). Patients with relevant comorbidities affecting systemic 
inflammatory response markers, such as chronic liver disease, 
immunosuppression, cytotoxic medication, hemato-oncologi-
cal disease, autoimmune disease, or acute infection status, 
were also excluded (n=4). Finally, 88 patients with pathologi-
cally proven RCC or TCC that showed an infiltrative growth 
pattern in MDCT were included in our study (Fig. 1).
Study variables and measurements of systemic 
inflammation
Blood samples were collected in calcium ethylenediaminetet-
raacetic acid tubes, and an auto-analyzer (XN-9000-Hematolo-
gy Analyzer, Sysmex, IL, USA) was used to evaluate ANC, ALC, 
AMC, NLR, and LMR as systemic inflammatory biomarkers. 
Blood counts were measured within 1 month prior to surgery.
Equipment and scanning
As described in detail by Keskin, et al.,11 all of the patients were 
examined using a 64-multidetector CT scanner (Siemens SO-
MATOM Sensation 64, Erlangen, Germany) set for 0.6-mm col-
limation, 3-mm slice thickness, 3-mm increments, 100 kV, 135 
mAs, pitch of 0.9, and a gantry rotation time of 0.33 s. A scout 
image was obtained first, followed by an unenhanced phase, 
corticomedullary phase (25 seconds after contrast injection), 
nephrographic phase (60 seconds after contrast injection), and 
excretory phase (5 minutes after contrast injection), sequentially. 
All patients received 100 mL of nonionic contrast medium (Ul-
travist 300; Bayer Schering Pharma, Berlin, Germany) with a 
flow rate of 5 mm/sec.
Statistical analysis
Kolmogorov-Smirnov and Shapiro-Wilk normality tests were 
used to verify the normal distribution of continuous variables. 
The differences between two groups for normally distributed 
variables were tested using an independent Student’s t-test, while 
the Mann-Whitney U test was used to compare non-parametri-
cally distributed variables. Normally distributed variables are 
expressed as median±SD, and non-parametrically distributed 
variables are expressed as median (IQR). The differences be-
tween the categorical variables were determined by a χ2-test.
Univariate and multivariate logistic regression analyses were 
performed to determine correlations with age, sex, tumor size, 
and systemic inflammatory biomarkers. In a multivariate mod-
el, significant variables in univariate analysis were taken into 
account. Odds ratios estimated from the logistic analyses are 
reported as relative risks with corresponding 95% confidence 
intervals (CIs).
Receiver operating characteristic (ROC) curve analysis was 
subsequently performed using the multivariable model. The 
area under the curve (AUC) was calculated. All statistical analy-
ses were performed using SPSS software version 20.0 (SPSS 
Inc., Chicago, IL, USA). All p-values <0.05 were considered sta-
tistically significant, and all statistical tests were two-sided.
RESULTS
A total of 63 patients with infiltrative RCC and 25 patients with 
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TCC were enrolled in our study. RCC patients were significantly 
younger than TCC patients (55.4±13.6 years vs. 69.7±10.2 years, 
p<0.001). Tumor size tended to be larger in the RCC group, with 
a mean size of 7.6±4.1 cm, compared to 6.1±3.1 cm for the TCC 
group; however, the difference was not statistically significant. 
Fewer than half of the patients in both groups showed nodal 
metastasis (Table 1). Likewise, there were more non-metastatic 
diseases than metastatic diseases. Infiltrative RCC patients 
tended to have high Fuhrman grades with clear cell dominant 
features.
ANC, AMC, and NLR did not statistically differ between the 
two groups (Table 2). ALC was significantly lower for the RCC 
group than the TCC group [1499/μL (1140, 1896) vs. 1860/μL 
(1433, 2342), p=0.016]. Likewise, LMR was significantly lower in 
the RCC group than in the TCC group [2.98 (2.32, 4.14) vs. 4.10 
(2.86, 6.09), p=0.011].
In subgroup analyses, ALC, NLR, and LMR significantly dif-
fered between the two groups in N0M0 renal masses (Table 3). 
In particular, ALC and LMR were useful markers for distin-
guishing small RCC and TCC tumors (≤ 4 cm) (p-values=0.020 
and 0.003, respectively). Conversely, no inflammatory bio-
marker was useful in distinguishing metastatic RCC from meta-
static TCC or in classifying a renal mass larger than 4 cm.
When we performed logistic regression within the non-met-
astatic group, young age at diagnosis, low ALC, and low LMR 
were significantly associated with RCC instead of TCC in uni-
variate analysis (Table 4). In multivariate analysis, age at diag-
nosis and LMR were the only two variables that were statistical-
ly significant differentiators of RCC and TCC, with young age 
and low LMR correlating with higher probability of RCC than 
TCC. The odds ratio (95% CI) for age at diagnosis was 0.874 
(0.778–0.982; p=0.024); for LMR it was 0.461 (0.214–0.994; 
p=0.048). We subsequently performed ROC curve analysis with 
probabilities extracted from the logistic regression, and the 
AUC was 0.919 (p<0.001), indicating strong correlations be-
tween RCC and younger age or LMR (date not shown). For the 
Fig. 1. (A and B) Pathologically proven infiltrative renal cell carcinoma and transitional cell carcinoma in preoperative multi-detector computed tomogra-
phy. (C and D) Cross sections of the pathologic specimens of each tumor after surgical resection.
A B
C D
391
Jang Hee Han, et al.
https://doi.org/10.3349/ymj.2017.58.2.388
small renal mass (≤4 cm) group, however, multivariate logistic 
regression analysis revealed no significant correlations with any 
parameters (Supplementary Table 1, only online).
DISCUSSION
About 6% of RCC cases involve infiltration of surrounding tis-
sues, appearing irregular and with ill-defined margins on MDCT. 
For this reason, in suspected RCC cases, MDCT is technically 
limited for excluding other infiltrative diseases and defining the 
correct diagnosis. Our study demonstrated the clinical useful-
ness of inflammatory biomarkers in distinguishing infiltrative 
RCC from TCC, which are the two most common infiltrative re-
nal diseases. The usefulness of these biomarkers is already es-
tablished in many other fields. These markers are widely used 
as prognostic factors not only for acute and chronic infections, 
but also for cancerous and non-cancerous inflammatory dis-
eases. Because inflammatory biomarker evaluation is relatively 
cheap and blood samples are easy to access, these parameters 
are important to consider as diagnostic tools.
Cancer has recently been considered to be as a disease of 
chronic inflammation. This classification is based on the patho-
logical presence of inflammatory cells and its related media-
tors, such as cytokines in tumor tissues. Furthermore, accord-
ing to Mantovani, et al.,23 tissue remodeling and angiogenesis 
processes in cancers are similar to those seen in chronic in-
flammatory responses and tissue repair. Additionally, Man-
tovani, et al.24 demonstrated that immature myeloid cells play a 
key role in both chronic infection and tumor microenviron-
ment.
RCC is one of the most well-known cancers associated with a 
pathogenesis that includes altered immune activity. Several 
studies demonstrate poorer prognosis in RCC patients with 
higher monocyte and neutrophils levels and lower lymphocyte 
counts.7 According to Frankenberger, et al.,25 growing RCC tu-
mors influence the activity of effector lymphocytes and modu-
late the composition of immune infiltrates. As the disease pro-
gresses, peripheral circulation are also affected as an increase 
in the number of circulating myeloid cells and regulatory T 
cells.
There are several reports that neutrophils and macrophages 
play major roles in RCC tumor progression. The level of circu-
lating monocytes can reflect the formation or presence of tu-
mor-associated macrophages. Many macrophage-released sol-
uble factors directly stimulate the growth of tumor cells and 
promote tumor cell migration and metastasis.9 Donskov, et al.7 
reported that among macrophage and neutrophil products, 
ROS may not only induce genomic instability, but also damage 
antitumor immune effector cells. Another study demonstrated 
that co-cultivation of tumor cells with macrophages leads to 
enhanced invasiveness of the malignant cells by TNF-α-
dependent MMP induction in the macrophages.24 Given these 
laboratory findings, clinical researchers have focused on the 
role of inflammatory biomarkers, especially monocyte and 
lymphocyte counts, in peripheral circulation as oncologic out-
come predictors or prognostic factors in RCC patients. Based 
on these above findings, the LMR has been assessed as a good 
candidate inflammatory biomarker for RCC. Several studies fo-
cused on the value of preoperative and postoperative LMR as 
an important prognostic factor in metastatic and non-metastat-
Table 1. Characteristics of Patients with Infiltrating Renal Cell Carcino-
mas (RCC) and RCC-Mimicking Transitional Cell Carcinomas (TCC)
RCC TCC p value
Number of patients enrolled 63 25
Age at diagnosis* 55.4±13.6 69.7±10.2 <0.001
Sex ratio (M:F)† 47:16 13:12 0.040
Tumor size (cm)* 7.6±4.1 6.1±3.1 0.105
Necrosis (%)‡ 7 (11.1) 1 (4.0) 0.431
Sarcomatoid change (%)‡ 11 (17.5) 3 (12.0) 0.749
Stage
pT stage, n (%)
pT1 14 (23.3) 1 (4.0)
pT2 4 (6.7) 0 (0)
pT3 34 (56.7) 15 (60.0)
pT4 8 (13.3) 9 (36.0)
pN stage, n (%)† 0.278
pNx/N0 43 (68.3) 14 (56.0)
pN+ 20 (31.7) 11 (44.0)
M stage, n (%)† 0.655
M0 41 (65.1) 15 (60.0)
M1 22 (34.9) 10 (40.0)
Fuhrman grade, n (%)
G1–2 7 (15.6)
G3–4 38 (84.4)
Histologic grade
Low grade 0 (0.0)
High grade 22 (100.0)
Histology, n (%)
Clear cell 36 (57.1)
Non-clear cell 27 (42.9)
M, male; F, female.
*Independent t-test, †χ2-test, ‡Fisher’s exact test.
Table 2. Inflammatory Biomarker Measurements in RCC and TCC
RCC (n=63) TCC (n=25)
p value
Median (IQR) Median (IQR)
ANC/µL 4631 (3714, 5996) 4816 (3837, 6659) 0.434
ALC/µL 1499 (1140, 1896) 1860 (1433, 2342) 0.016
AMC/µL 474 (379, 591) 448 (329, 558) 0.544
NLR 2.86 (2.08, 4.88) 2.28 (1.66, 4.17) 0.203
LMR 2.98 (2.32, 4.14) 4.10 (2.86, 6.09) 0.011
RCC, renal cell carcinoma; TCC, transitional cell carcinoma; ANC, absolute 
neutrophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte 
count; NLR, neutrophil-lymphocyte ratio; LMR, lymphocyte-monocyte ratio.
All variables examined by Mann-Whitney test.
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ic RCC patients.9,26-29
Additionally, there are several reports of a predictive role for 
LMR in upper urinary tract TCC. Elevated preoperative LMR 
also has prognostic value in non-metastatic upper urinary tract 
TCC.30 Furthermore, the presence of neutrophilia with relative 
lymphocytopenia predicts a worse oncological prognosis in pa-
tients with localized upper urinary tract TCC.31-33
As a novel perspective, we focused on the possibility that in-
flammatory biomarkers could distinguish RCC from other infil-
trative renal masses, especially TCC that mimics RCC on diag-
nostic images. We hypothesized that infiltrative RCC and TCC 
might demonstrate different degrees of biomarker changes due 
to differences in tumor biology. Of the 63 pathologically-proven 
RCC patients in our study, more than half (35/63, 55.6%) re-
quired renal biopsy (20/63, 31.7%) or diagnostic ureterorenos-
copy (15/63, 23.8%). Eight (12.7%) cases of pathologically-proven 
RCC underwent nephroureterectomy instead of nephrectomy, 
due to relatively low suspicion of RCC in preoperative MDCT. 
Likewise, of the 25 pathologically-proven TCC patients, 15 
(60%) underwent renal biopsy or diagnostic ureterorenoscopy 
preoperatively. Six patients (24%) underwent nephrectomy in-
stead of nephroureterectomy, and consequently required sub-
sequent remnant-ureterectomy surgery. Overall, about 16% of 
infiltrative renal masses in our cohort were misdiagnosed pre-
operatively, and underwent inappropriate surgery. Adding cy-
tology results also did not help. Among 25 pathologically-prov-
en TCC patients, cytology was performed in 16 cases. Only 2 
cases out of 16 (12.5%) showed positive results for TCC.
Previous studies report that as RCC tumor burden grows, the 
values of NLR and LMR increase and decrease, respectively. We 
performed subgroup analysis to see if the biomarker parame-
ters could be diagnostically relevant in cases with relatively 
lower tumor burden. We especially focused on the clinical 
power of inflammatory biomarkers as tools for diagnosis in sur-
gical candidates without metastasis. In the non-metastatic 
group, we identified ALC, NLR, and LMR as potential biomark-
ers that distinguished infiltrative RCC from TCC. Logistic re-
gression analysis revealed that LMR is the only significant use-
ful inflammatory biomarker for distinguishing RCC from TCC. 
In the ROC curve analysis, the AUC was 0.817 (p-value=0.002), 
Table 3. Inflammatory Biomarker Associations with Pathological Parameters in Subgroups of Infiltrative RCC and TCC
Non metastatic renal mass (n=46) Metastatic renal mass (n=42)
RCC (n=36) TCC (n=10) p value RCC (n=27) TCC (n=15) p value
ANC/µL 4161 (3154, 4925) 4076 (2845, 4697) 0.537 5770 (4430, 6584) 5945 (4627, 8663) 0.423
ALC/µL 1599 (1153, 2008) 2227 (1550, 2544) 0.021 1335 (981, 1766) 1747 (1331, 2153) 0.101
AMC/µL 448 (351, 578) 368 (256, 497) 0.108 501 (399, 616) 480 (427, 641) 0.783
NLR 2.54 (1.96, 4.04) 1.66 (1.41, 2.38) 0.020 4.6 (2.35, 7.05) 3.31 (1.96, 6.23) 0.572
LMR 3.69 (2.54, 4.43) 5.78 (3.79, 7.57) 0.002 2.55 (2.05, 4.07) 3.90 (2.29, 5.47) 0.176
Small renal mass (≤4 cm) (n=21) Non-small renal mass (>4 cm) (n=67)
RCC (n=13) TCC (n=8) p value RCC (n=50) TCC (n=17) p value
ANC/µL 3819 (2724, 6510) 3900 (3063, 5392) 1.000 4790 (1169, 1910) 5945 (4172, 7993) 0.103
ALC/µL 1501 (1079, 2022) 2166 (1795, 2372) 0.020 1489 (1169, 1910) 1741 (1259, 2380) 0.185
AMC/µL 430 (337, 595) 396 (256, 445) 0.185 487 (381, 597) 513 (347, 645) 0.614
NLR 2.53 (2.00, 4.46) 1.81 (1.43, 2.79) 0.076 3.02 (2.08, 5.01) 3.31 (1.93, 5.86) 0.885
LMR 3.76 (2.41, 4.83) 5.74 (4.66, 7.86) 0.003 2.82 (2.26, 4.13) 3.74 (2.39, 5.51) 0.306
RCC, renal cell carcinoma; TCC, transitional cell carcinoma; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; 
NLR, neutrophil-lymphocyte ratio; LMR, lymphocyte-monocyte ratio.
Table 4. Univariate and Multivariate Analysis of Correlations between Demographic and Blood Count Variables with Non-Metastatic Infiltrative Renal 
Cell Carcinoma
Variables
Univariate analysis Multivariate analysis
OR (95% CI) p value OR (95% CI) p value
Age at diagnosis 0.85 (0.768–0.950) 0.004 0.87 (0.778–0.982) 0.024
Size (cm) 1.10 (0.870–0.139) 0.444
Male 1.14 (0.201–6.494) 0.880
ANC/µL 1.00 (1.000–1.001) 0.400
AMC/µL 1.00 (0.999–1.010) 0.125
ALC/µL 0.998 (0.997–1.000) 0.019 1.00 (0.998–1.003) 0.728
NLR 2.32 (0.944–5.718) 0.067
LMR 0.44 (0.249–0.775) 0.005 0.46 (0.214–0.994) 0.048
OR, odds ratio; CI, confidence interval; ANC, absolute neutrophil count; AMC, absolute monocyte count; ALC, absolute lymphocyte count; NLR, neutrophil-lym-
phocyte ratio; LMR, lymphocyte-monocyte ratio.
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and the cut off value was 5.250 (data not shown). This value is 
slightly higher than the already mentioned values ranging from 
3.0–5.2 as an independent prognostic factor. Furthermore, in 
patients with small renal masses less than 4 cm, we confirmed 
that ALC and LMR could be helpful in distinguishing RCC from 
TCC by Mann-Whitney U tests (Table 3), although multivariate 
regression showed no statistically significant biomarkers. With 
the help of these biomarkers, we may avoid choosing the wrong 
surgical method in planning resections; moreover, we may be 
able to recommend additional preoperative renal biopsies or 
diagnostic ureterorenoscopies in cases of mismatch between 
imaging results and biomarker results. Nevertheless, the in-
flammatory biomarkers were less effective in distinguishing in-
filtrative large (>4 cm) or metastatic cancers. We think this re-
sult originated from the common biologic characteristics of 
metastatic solid cancers. According to the results of a meta-anal-
ysis performed by Teng, et al.,34 increased pretreatment LMR is 
correlated with significantly favorable outcomes in patients 
with general solid tumors. Although the exact mechanism of 
the prognostic value of LMR in solid tumor is poorly under-
stood, we could infer that the effect of cancer-related inflam-
mation could be maximized for general advanced solid cancers 
with metastasis, obscuring the role of inflammatory biomarkers 
in distinguishing cancer types.
This study focused primarily on non-metastatic infiltrative 
renal masses. For patients with lesions of this nature, we typi-
cally consider surgical resection regardless of the exact pathol-
ogy. By simple calculations based on a basic blood workup, 
urologists can gain insight into the type of infiltrative lesion for 
designing surgical plans in preoperative settings.
The current study has several limitations. First, although we 
attempted to control for possible confounding factors that 
could lead to biased results, this was a retrospective study with 
a relatively small number of patients. Another potential limita-
tion is that we did not compare serum LMR with the extent of 
inflammatory cell infiltration within and surrounding tumor 
tissue. Such histological correlation should be considered in fu-
ture analyses. However, even considering these limitations, we 
believe our study outlines the clinically benefits of the noted 
biomarkers in distinguishing infiltrative RCC from TCC.
In conclusion, inflammatory biomarkers could be helpful in 
distinguishing infiltrative renal masses. Younger age and lower 
LMR are more likely to imply infiltrative RCC rather than TCC. 
Using these inflammatory biomarkers in conjunction with ra-
diological imaging, non-metastatic infiltrative RCC could be di-
agnosed with greater certainty.
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